Localized prostate cancer: Quality of life meets Whitmore's legacy

Journal of the National Cancer Institute

Volumn 96, Issue 18, 2004, Pages 1348-1349

  Bermejo, Carlos ^a   Kristal, Alan R ^b   Zeliadt, Steven B ^b   Ramsey, Scott ^b   Thompson, Ian M ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DIAPER; DISEASE COURSE; EDITORIAL; EVIDENCE BASED MEDICINE; FECES INCONTINENCE; HEALTH CARE PLANNING; HUMAN; IMPOTENCE; INFORMED CONSENT; INTESTINE EXAMINATION; MALE; MATERIALS HANDLING; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; PATIENT ATTITUDE; PATIENT MONITORING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNITED STATES; URINE INCONTINENCE; ADJUVANT THERAPY; BLOOD; DECISION MAKING; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; IMMUNOLOGY; MASS SCREENING; NOTE; PATIENT PARTICIPATION; PREDICTION AND FORECASTING; PROSTATE TUMOR; STANDARD;

DECISION MAKING; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EARLY DIAGNOSIS; FECAL INCONTINENCE; HUMANS; MALE; MASS SCREENING; PATIENT PARTICIPATION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; URINARY INCONTINENCE;

EID: 4644233846     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh282     Document Type: Editorial

References (9)

1. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004;96:1358-67.
2. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
3. Whitmore WF Jr, Warner JA, Thompson IM Jr. Expectant management of localized prostatic cancer. Cancer 1991;67:1091-6.
4. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
5. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996;88:166-73.
6. Swanson GP, Riggs MW, Earle JD. Long-term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:406-11.
7. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
8. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy, compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
9. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.